Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
silarvirovir
- Development stage
- Phase 2
- Lead developer
- Ginkgo Tree Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Silarvirovir (GKT-001) is a small molecule NS3/4A protease inhibitor developed by Ginkgo Tree Pharmaceutical (Suzhou) for the treatment of chronic hepatitis C virus (HCV) infection. It is typically administered as silarvirovir potassium. In clinical trials, it has been evaluated in combination with other direct-acting antivirals (DAAs) like sofosbuvir, specifically targeting genotypes 2, 3, and 6 in non-cirrhotic patients. The drug works by inhibiting the NS3/4A serine protease, an enzyme essential for HCV polyprotein processing and viral replication. By blocking this protease, silarvirovir prevents the formation of functional viral proteins, thereby halting the viral lifecycle.
- Other names
- silarvirovir potassium赛拉瑞韦
02
Targets
NSP3 (SARS-CoV-2 non-structural protein 3)NS4A (Hepatitis C virus NS4A)
Beyond the preview
Go deeper on silarvirovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on silarvirovir.